openPR Logo
Press release

Angelman Syndrome Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies | Neuren Pharma, Ultragenyx, Ionis, Roche,

05-17-2023 09:59 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Angelman Syndrome Pipeline Assessment (2023 Updates) |

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Angelman Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Angelman Syndrome Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Angelman Syndrome Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Angelman Syndrome Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Angelman Syndrome Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Angelman Syndrome treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Angelman Syndrome market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the Angelman Syndrome Therapeutics Domain:
https://www.delveinsight.com/report-store/angelman-syndrome-pipeline-insight?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Angelman Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr

Angelman Syndrome Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Angelman Syndrome. Currently, Neuren Pharmaceuticals is leading the therapeutics market with its Angelman Syndrome drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Angelman Syndrome Therapeutics Market Include:
• Neuren Pharmaceuticals
• Ultragenyx Pharmaceutical
• Ionis Pharmaceuticals
• Roche
• GEXVal
• PTC Therapeutics
• Taysha Gene Therapies
• Ovid Therapeutics
• GeneTX Biotherapeutics, LLC
• Ultragenyx Pharmaceutical Inc
• Hoffmann-La Roche
• Ovid Therapeutics Inc.
• Biogen
And Many Others

Angelman Syndrome Emerging and Marketed Therapies Covered in the Report Include:
• GT-AS: PTC Therapeutics
• GTX-102: Ultrageny Pharmaceutical
• GXV 001: GEXVal
• NNZ-2591: Neuren Pharmaceuticals
• RG 6091: Roche
And Many More

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Angelman Syndrome Current Treatment Patterns
4. Angelman Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Angelman Syndrome Late-Stage Products (Phase-III)
7. Angelman Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Angelman Syndrome Discontinued Products
13. Angelman Syndrome Product Profiles
14. Angelman Syndrome Key Companies
15. Angelman Syndrome Key Products
16. Dormant and Discontinued Products
17. Angelman Syndrome Unmet Needs
18. Angelman Syndrome Future Perspectives
19. Angelman Syndrome Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr

Other Trending Healthcare Reports by DelveInsight -
Bronchial Neoplasm Market
https://www.delveinsight.com/report-store/bronchial-neoplasm-market

Gastro Intestinal Bleeding Market
https://www.delveinsight.com/report-store/gastro-intestinal-bleeding-market

Orthostatic Hypotension Market
https://www.delveinsight.com/report-store/orthostatic-hypotension-market

Pars Plantis Market
https://www.delveinsight.com/report-store/pars-plantis-market

Schistosomiasis Market
https://www.delveinsight.com/report-store/schistosomiasis-market

Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market

Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market

Osteochondrodysplasia Market
https://www.delveinsight.com/report-store/osteochondrodysplasia-market

Tuberous Sclerosis Complex Market
https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market

Ocular Melanoma Market
https://www.delveinsight.com/report-store/ocular-melanoma-market

Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market

Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market

Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market

Cryptococcosis Market
https://www.delveinsight.com/report-store/cryptococcosis-market

Gene Therapy for Ocular Rare Disease Market
https://www.delveinsight.com/report-store/gene-therapy-for-ocular-rare-disease-market

Hypersomnia Market
https://www.delveinsight.com/report-store/hypersomnia-market

CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market

Drug Hypersensitivity Market
https://www.delveinsight.com/report-store/drug-hypersensitivity-market

Tendonitis Market
https://www.delveinsight.com/report-store/tendonitis-market

Polypoidal Choroidal Vasculopathy (PCV) Market
https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market

Secondary Hyperparathyroidism Market
https://www.delveinsight.com/report-store/secondary-hyperparathyroidism-market

Peripheral Neuritis Market
https://www.delveinsight.com/report-store/peripheral-neuritis-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Angelman Syndrome Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies | Neuren Pharma, Ultragenyx, Ionis, Roche, here

News-ID: 3057715 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Angelman

Angelman Syndrome Market Is Booming Worldwide 2025-2032 | Roche Biogen,Ionis Pha …
According to the latest research from Coherent Market Insights, the Angelman Syndrome Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough research, highlighting current trends, financial performance, and historical data evaluation. The company profiles within the report are derived from the current performance of the Angelman Syndrome Market, considering key factors such as drivers, trends, and challenges, as
Angelman Syndrome Treatment Market Size is expected to grow by 2034, estimates D …
Angelman Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Angelman Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence. DelveInsight's "Angelman Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Angelman Syndrome, historical and
Angelman Syndrome Treatment Market Size, Treatment Drugs Report 2034
Angelman Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Angelman Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence. DelveInsight's "Angelman Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Angelman Syndrome, historical and
Angelman Syndrome Treatment Market Size is expected to grow by 2034, estimates D …
Angelman Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Angelman Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence. DelveInsight's "Angelman Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Angelman Syndrome, historical and
Angelman Syndrome Treatment Market Insight Business Opportunities, Revenue, Gros …
The incidence of angelman syndromes can vary among different populations and age groups. However, the increase in government initiatives in developing treatment options for angelman syndrome drives the global angelman syndrome treatment market. Moreover, increased health and R&D expenditure also boosts the market growth. Data Bridge Market Research analyses that the angelman syndrome treatment market which was USD 143.77 million in 2022, would rocket up to USD 220.64 million
Angelman Syndrome Market Report 2023-2033 | Industry Size, Analysis and Latest I …
Market Overview: The 7 major Angelman syndrome markets are expected to exhibit a CAGR of 4.4% during 2023-2033. The report offers a comprehensive analysis of the angelman syndrome market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven